Clinical Trial: A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer

U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489287) titled 'A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer' on March 19.

Brief Summary: This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.

Study Start Date: June 15, 2026

Study Type: INTERVENTIONAL

Condition: Platinum-resistant Ovarian Cancer

Intervention: BIOLOGICAL: GB-5267 - IV only

IV infusion

BIOLOGICAL: GB-5267 -Combined IV and IP Infusion

IV and IP Infusion

Recruitment Status: NOT_YET_RECRUI...